Brian Alexander: Honored to participate in the NCI’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice
Brian Alexander, CEO of Foundation Medicine, shared a post by Foundation Medicine on LinkedIn, adding;
“Honored to participate in the National Cancer Institute (NCI)’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.”
Qouting Foundation Medicine‘s post:
“Proud to announce our participation in the National Cancer Institute (NCI)’s Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer. This initiative is the largest of its kind to test the effectiveness of biomarker-targeted cancer treatment combinations to seek improvement in patient outcomes. Foundation Medicine is one of the largest contributors of potential participants to ComboMATCH, in connection with which Foundation Medicine testing results will help determine trial eligibility for patients. ”
Read more at the link here.
For the video attached to the post click here.
Source: Brian Alexander/LinkedIn and Foundation Medicine/LinkedIn